PFS
Extended Data Fig. 3 · Panel A
Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Wei Li, Junji Tsurutani, Naoto T Ueno, Khalil Zaman, Aleix Prat, Konstantinos Papazisis, Hope S Rugo, Toshinari Yamashita, Nadia Harbeck, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Xiaojia Wang, Andrea Gombos, Eriko Tokunaga, Cecilia Orbegoso Aguilar, Lotus Yung, Feng Xiao, Yingkai Cheng, David Cameron
Nat Med 31(12) 4205-4213
In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55-0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55-0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%-10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029 .
1 个 Figure · 2 个 KM 面板
Kaplan-Meier analysis of PFS by investigator in (a) HR+ and (b) HR− cohorts. CI, confidence interval; HR, hormone receptor; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician’s choice of chemotherapy. For the OS and PFS by investigator endpoints for the HR+ and all patient cohorts, the HR status is based on data collected using the interactive web-response and voice-response system at the time of randomization, which includes patients who were misstratified.
Extended Data Fig. 3 · Panel A
Panel A 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 3 · Panel B
Panel B 是同一 Extended Data Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。